Please login to the form below
parathyroid hormone
This page shows the latest parathyroid hormone news and features for those working in and with pharma, biotech and healthcare.
FDA rejects Amgen's osteoporosis hope romosozumab
Tymlos is a parathyroid hormone-related protein (PTHrP) analogue that competes most closely with Eli Lilly's ageing osteoporosis drug Forteo (teriparatide) and could become a $1bn-plus product at peak,
Latest news
-
Shire finally bags EU approval for rare disease drug Natpar
US. Natpar - which is sold as Natpara in the US - has been given a conditional approval by the European Medicines Agency and becomes the first and only licenced recombinant human parathyroid ... hormone therapy for chronic hypoparathyroidism, a rare
-
NICE set to back Parsabiv for kidney disease complication
It involves excessive secretion of parathyroid hormone by the parathyroid glands in response to decreased kidney function, and causes bone pain, reduced mobility, stomach pain and depression.
-
J&J gets CHMP backing for broader Darzalex use
ahead for Natpara (parathyroid hormone), a treatment for patients with chronic hypoparathyroidism who cannot be adequately controlled with standard treatment with calcium and vitamin D.
-
Amgen wins European approval for Parsabiv
Clinical trials have suggested Parsabiv is as good as Sensipar in reducing parathyroid hormone levels in sHPT, and more effective than Sensipar in terms of the number of patients experiencing
-
Amgen's Kyprolis scarred by head-to-head duel with Velcade
This has led some analysts to suggest Amgen and UCB will have trouble competing with potential rivals such as Radius Health's parathyroid hormone analog abaloparatide, which performed better on
More from news
Approximately 1 fully matching, plus 19 partially matching documents found.
Latest Intelligence
-
Pharma deals in June 2015
The device, which has been tested in the clinic for the delivery of parathyroid hormone in osteoporosis patients, can be programmed to release drug at precise times and on a
-
Deal Watch table for December 2014
Collaboration, licence. 581. Opko Health / Pfizer. Long-acting hGH-CTP for growth hormone deficiency in adults and children (p3). ... ZP-PTH (parathyroid hormone 1-34) delivered via microneedle patch system (p2). Licence.
-
Pharma deals during December 2014
Lilly's second drug delivery-based deal of the month is the $440m licence with Alza spin-out Zosano Pharma for ZP-PTH, a phase II formulation of parathyroid hormone ... which is currently in phase III trials for the treatment of growth hormone deficiency
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- Genmab hires first chief operating officer
- A relentless commitment to neuroscience
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
